Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand.

Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence BioMed has spent the past year advancing a purpose-built platform designed to support ibogaine-based programs across development and potential commercialization.

Through its investment in and collaboration with PsyLabs, the Company has established an integrated supply and GMP-compliant manufacturing platform spanning sourcing at origin, extraction, purification, and pharmaceutical production. This platform is designed to enable consistent, high-quality output while supporting the requirements of clinical and regulated environments.

Operating at the natural source of ibogaine in Africa, PsyLabs has secured direct access to raw materials and in-region processing capabilities, supporting traceability, supply continuity, and ethical sourcing practices aligned with long-term sustainability and community engagement.

The Company is positioned to support partners across the value chain – from early-stage research through to clinical development and potential commercialization – helping to facilitate program advancement and supply in a market where access to pharmaceutical-grade ibogaine remains limited.

Globally, pharmaceutical-grade ibogaine supply remains limited, fragmented, and largely non-integrated, making access to standardized, GMP-compliant material a critical constraint on clinical progress. Psyence BioMed's vertically integrated platform, supported by its GMP inventory, is designed to help address this gap.

A Commercial Moat: GMP Doses Ready for Research

As a key operational milestone, the Company confirms it currently holds standardized, stabilized, and GMP-compliant ibogaine doses in inventory. This supply is designed to support ongoing and future research initiatives, providing immediate access to pharmaceutical-grade material and helping to reduce delays associated with supply constraints.

In addition to high-purity ibogaine, the Company supports the development of total alkaloid extracts, enabling flexibility across therapeutic approaches and supporting continued research into both single-compound and full-spectrum modalities.